ASCO Genitourinary Symposium

Long-Term, High-Dose Radiation, ADT Boosts Survival in Prostate Cancer

January 30th 2024, 8:00pm

Article

Patients with high-risk prostate cancer who had a higher dose of radiation plus long-term androgen deprivation therapy tended to live longer than those who had a lower dose.

Kidney Cancer Subtypes, Tumor Stages May Predict Recurrence, Prognosis

January 30th 2024, 2:00pm

Article

Real-world data demonstrated that knowing a patient’s stage and subtype of renal cell carcinoma, a type of kidney cancer, may provide cancer teams with the information needed to determine potential prognosis and recurrence risk.

Injectable Opdivo May Mitigate Disparities in Kidney Cancer

January 29th 2024, 11:00pm

Video

Subcutaneous Opdivo led to similar outcomes to intravenous administration of the drug and may be easier to access down the road, an expert said.

Postsurgical Keytruda Boosts Survival in Clear Cell Renal Cell Carcinoma

January 29th 2024, 10:00pm

Article

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Opdivo Misses Disease-Free Survival Goal in Kidney Cancer Trial

January 29th 2024, 5:00pm

Article

Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.

Adstiladrin Leads to Beneficial Outcomes in Some Bladder Cancers

January 29th 2024, 4:00pm

Article

Urinary minimal residual disease-negative status was related to preventing the return of cancer when certain patients with bladder cancer received Adstiladrin.

Keytruda Improves Disease-Free Survival in Advanced Bladder Cancer

January 28th 2024, 8:00pm

Article

Postsurgical Keytruda improved disease-free survival — but not overall survival — in patients with locally advanced, muscle-invasive bladder cancer.

Survival Benefits with Keytruda and Padcev in Advanced Urothelial Cancer

January 28th 2024, 2:00pm

Article

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.

No Increased Blood-Related Side Effects With Radium-223 in Prostate Cancer

January 27th 2024, 8:00pm

Article

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.

Keytruda Plus Cabometyx Produces Responses in Cisplatin-Ineligible Bladder Cancer

January 27th 2024, 6:00pm

Article

Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer.